![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Grants Advaxis’ Immunotherapy Drug Fast Track Status
FDA Grants Advaxis’ Immunotherapy Drug Fast Track Status
The FDA has awarded fast track designation to Advaxis’ investigational immunotherapy ADXS-HER2 to treat patients with newly diagnosed, non-metastatic, surgically resectable osteosarcoma.
The candidate is being developed to target HER2-expressing cancers, such as breast, gastric, esophageal and osteosarcoma cancers. ADXS-HER2 is being studied as a monotherapy in a Phase 1b trial. It received orphan designation from the FDA and EMA.
Upcoming Events
-
21Oct